https://ansm.sante.fr/tableau-atu-rtu/177lu-lu-psma-617-solution-injectable-pour-perfusion 2023 false false false France French Lutetium Lu 177 Vipivotide Tetraxetan Pluvicto drug information lutetium (177Lu) vipivotide tetraxetan
--- https://www.has-sante.fr/jcms/p_3358995/fr/-177lu-lu-psma-617-cancer-de-la-prostate https://www.has-sante.fr/jcms/p_3359005/fr/decision-n2022-0249/dc/sem-du-13-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-177lu-lu-psma-617-1000-mbq/ml-solution-injectable/pour-perfusion 2022 false false false France treatment outcome insurance, health, reimbursement adult PSMA-Positive Tumor Metastatic Prostate Carcinoma guidelines for drug use evaluation of the transparency committee prostatic neoplasms, Castration-Resistant Pluvicto
--- https://www.cadth.ca/fr/vipivotide-tetraxetan-marque-au-lutetium 2022 false false false Canada French drug evaluation Lutetium Lu 177 Vipivotide Tetraxetan prostatic neoplasms, Castration-Resistant neoplasm metastasis FOLH1 protein, human PSMA-Positive Tumor lutetium (177Lu) vipivotide tetraxetan Pluvicto